Faheem joined the Mirati Board of Directors in 2019 as Chairman of the Board. Additionally, Faheem is currently Chairman of Sente Labs, Inc. and Aspen Neuroscience, lead independent director on the Kura Oncology, Inc. board, and Chairman of Gossamer Bio, Inc. Gossamer Bio has a specific focus on the discovery and development of novel and differentiated therapeutic products to address high unmet needs amongst various targeted patient populations.
Prior to joining Gossamer Bio, Faheem served as President, CEO and a Director of Receptos, Inc. from 2010 to 2015, when Receptos was acquired by Celgene Corporation. Previously, Faheem was the President, Chief Executive Officer and a director of Facet Biotech Corporation, a biology-driven antibody company with a focus in multiple sclerosis and oncology. He held that position from 2008 until the company’s acquisition by Abbott Laboratories in 2010.
Faheem’s career has also encompassed various leadership roles including President, Chief Executive Officer and a director of PDL BioPharma, Inc. from 2008 until 2008. From 2004 to 2008, Faheem served as multiple positions at Biogen Idec Inc., a biotechnology company specializing in neurological disorders, autoimmune disorders and cancer—the latest being Executive Vice President in charge of the oncology/rheumatology strategic business unit. Faheem also held roles with Bristol Myers Squibb, where he was President of the Oncology Therapeutics Network, and GlaxoSmithKline and its predecessor organizations, for 14 years. Prior board experiences include service on the board of directors of Vital Therapies, Inc., Tocagen, Ambit Biosciences Corporation, Seragon Pharmaceuticals, Somaxon Pharmaceuticals, Aragon Pharmaceuticals and Tercica, Inc.
Faheem received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.